Fig. 1: Iloperidone treatment resulted in higher change from baseline in urate blood levels as compared to placebo or active comparator ziprasidone after four weeks. | The Pharmacogenomics Journal

Fig. 1: Iloperidone treatment resulted in higher change from baseline in urate blood levels as compared to placebo or active comparator ziprasidone after four weeks.

From: A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone

Fig. 1: Iloperidone treatment resulted in higher change from baseline in urate blood levels as compared to placebo or active comparator ziprasidone after four weeks.

a Schematic diagram depicting the 4-week, randomized, blinded, clinical trial design/schema generalizable to both studies. b Mean change from baseline for serum urate for observed cases in Study 3201 and Study 3101. Error bars represent standard error of the mean (SEM). c Least squares (LS) mean difference for change in serum urate and p-values for ANCOVA between iloperidone and placebo. Refer to Tables 1 and 2 for a tabular presentation of numeric results of LS mean P-values, and 95% CIs.

Back to article page